PEARKO Therapeutics Inc.

PEARKO Therapeutics Inc. is rated 3 out of 5 in the category innovative therapies for cardiovascular disease.. Read and write reviews about PEARKO Therapeutics Inc.. PEARKO Therapeutics Inc. is a biopharmaceutical company engaged in the practice of translational medicine: catalyzing and driving the translation of molecular discoveries to patients. We are primarily focused on novel and innovative therapies for cardiovascular diseases, which carry a significant physical and financial burden on patients and our healthcare systems, and which remain the leading cause of death worldwide. PEARKO Therapeutics intends to address these critical medical issues by providing pharmacological therapies to patients with cardiovascular disease through innovative technologies. PEARKO Therapeutics has established itself in the field of biopharmaceuticals with its innovative biologic product, apelin analog therapy, as a treatment for patients with heart failure, pulmonary arterial hypertension; and for patients at risk of, or who have experienced, myocardial infarction (heart attack). This unique apelin analog acts as a substitute to the innate apelin peptide, which is downregulated in cardiovascular disease, to promote the activation of protective pathways in the cardiovascular system. This ultimately serves to improve patient outcomes and quality of life through a promoted recovery process. Our patented formulations are more stable and longer-lasting than the innate peptide, bioactive for over 24 hours, as opposed to minutes. In addition, PEARKO Therapeutics continues to develop other biologics to treat cardiovascular diseases.